Journal of Immunology Research / 2011 / Article / Tab 2

Research Article

HLA- 57 and Gender Influence the Occurrence of Tuberculosis in HIV Infected People of South India

Table 2

(a) Frequency distribution of HLA A alleles among HIV positive subjects with and without TB and among healthy renal donors (control sample). (b) Frequency distribution of HLA B alleles among HIV positive subjects with and without TB and among healthy renal donors (control sample). (c) Frequency distribution of HLA DR alleles among HIV positive subjects with and without TB and among healthy renal donors (control sample).
(a)

HLA AHIV positive femalesHIV positive malesHealthy renal donors
TB neg. FTB pos. FTB neg. MTB pos. MFemalesMales

129 (33.0%)9 (30.0%)14 (23.7%)15 (24.6%)84 (22.3%)65 (21.2%)
227 (30.7%)12 (40.0%)20 (33.9%)19 (31.1%)115 (30.6%)95 (31.0%)
310 (11.4%)3 (10.0%)10 (16.9%)7 (11.5%)54 (14.4%)32 (10.5%)
101 (1.1%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0%)0 (0%)
1123 (26.1%)7 (23.3%)13 (22.0%)17 (27.9%)96 (25.5%)82 (26.8%)
231 (1.1%)0 (0.0%)0 (0.0%)1 (1.6%)2 (0.5%)10 (3.3%)
2420 (22.7%)8 (26.7%)16 (27.1%)20 (32.8%)97 (25.8%)79 (25.8%)
250 (0.0%)0 (0.0%)0 (0%)0 (0%)1 (0.3%)1 (0.3%)
265 (5.7%)2 (6.7%)3 (5.1%)5 (8.2%)23 (6.1%)23 (7.5%)
292 (2.3%)4 (13.3%)3 (5.1%)3 (4.9%)17 (4.5%)10 (3.3%)
301 (1.1%)0 (0.0%)1 (1.7%)2 (3.3%)10 (2.7%)14 (4.6%)
318 (9.1%)1 (3.3%)6 (10.2%)1 (1.6%)28 (7.4%)28 (9.2%)
324 (4.5%)1 (3.3%)4 (6.8%)3 (4.9%)17 (4.5%)10 (3.3%)
3315 (17.0%)5 (16.7%)11 (18.6%)11 (18.0%)93 (24.7%)72 (23.5%)
340 (0.0%)0 (0.0%)1 (1.7%)0 (0.0%)0 (0%)1 (0.3%)
360 (0.0%)0 (0.0%)1 (1.7%)0 (0.0%)2 (0.5%)5 (1.6%)
430 (0.0%)0 (0.0%)0 (0%)0 (0%)1 (0.3%)0 (0%)
660 (0.0%)0 (0.0%)0 (0%)0 (0%)0 (0%)2 (0.7%)
6813 (14.8%)6 (20.0%)7 (11.9%)9 (14.8%)51 (13.6%)32 (10.5%)
740 (0.0%)0 (0.0%)0 (0%)0 (0%)2 (0.5%)5 (1.6%)
800 (0.0%)0 (0.0%)0 (0%)0 (0%)1 (0.3%)0 (0%)

(b)

HIV positive femalesHIV positive malesHealthy renal donors
HLA BTB neg. FTB pos. FTB neg. MTB pos. MFemalesMales

718 (20.5%)5 (16.7%)13 (22.0%)10 (16.4%)71 (18.9%)48 (15.7%)
84 (4.5%)4 (13.3%)2 (3.4%)4 (6.6%)5 (1.3%)13 (4.2%)
132 (2.3%)1 (3.3%)1 (1.7%)4 (6.6%)23 (6.1%)28 (9.2%)
152 (2.3%)1 (3.3%)2 (3.4%)0 (0.0%)7 (1.9%)13 (4.2%)
180 (0.0%)1 (3.3%)2 (3.4%)4 (6.6%)12 (3.2%)12 (3.9%)
214 (4.5%)2 (6.7%)3 (5.1%)2 (3.3%)0 (0.0%)4 (1.3%)
275 (5.7%)1 (3.3%)2 (3.4%)1 (1.6%)9 (2.4%)12 (3.9%)
3515 (17.0%)8 (26.7%)18 (30.5%)20 (32.8%)104 (27.7%)75 (24.5%)
379 (10.2%)3 (10.0%)4 (6.8%)8 (13.1%)26 (6.9%)26 (8.5%)
380 (0.0%)0 (0.0%)2 (3.4%)3 (4.9%)10 (2.7%)8 (2.6%)
390 (0.0%)1 (3.3%)0 (0.0)%1 (1.6%)3 (0.8%)8 (2.6%)
410 (0.0%)0 (0.0%)0 (0.0)%1 (1.6%)1 (0.3%)4 (1.3%)
421 (1.1%)0 (0.0%)0 (0.0)%0 (0.0%)1 (0.3%)3 (1.0%)
447 (8.0%)1 (3.3%)11 (18.6)%8 (13.1%)51 (13.6%)51 (16.7%)
450 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)2 (0.5%)2 (0.7%)
470 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)2 (0.7%)
480 (0.0%)0 (0.0%)2 (3.4%)0 (0.0%)6 (1.6%)3 (1.0%)
491 (1.1%)1 (3.3%)0 (0.0)%1 (1.6%)7 (1.9%)3 (1.0%)
502 (2.3%)0 (0.0%)2 (3.4%)1 (1.6%)9 (2.4%)7 (2.3%)
5118 (20.5%)8 (26.7%)16 (27.1%)14 (23.0%)59 (15.7%)34 (11.1%)
5215 (17.0%)0 (0.0%)6 (10.2%)6 (9.8%)37 (9.8%)36 (11.8%)
530 (0.0%)1 (3.3%)1 (1.7%)0 (0.0%)9 (2.4%)10 (3.3%)
552 (2.3%)1 (3.3%)1 (1.7%)2 (3.3%)6 (1.6%)5 (1.6%)
563 (3.4%)0 (0.0%)0 (0.0)%0 (0.0%)7 (1.9%)3 (1.0%)
5719 (21.6%)2 (6.7%)1 (1.7%)4 (6.6%)48 (12.8%)29 (9.5%)
584 (4.5%)1 (3.3%)3 (5.1%)3 (4.9%)33 (8.8%)25 (8.2%)
4023 (26.1%)10 (33.3%)8 (13.6%)12 (19.7%)13 (3.5%)13 (4.2%)
606 (6.8%)1 (3.3%)3 (5.1%)1 (1.6%)26 (6.9%)14 (4.6%)
6117 (19.3%)9 (30.0%)5 (8.5%)11 (18.0%)51 (13.6%)38 (12.4%)
628 (9.1%)0 (0.0%)4 (6.8%)3 (4.9%)18 (4.8%)15 (4.9%)
630 (0.0%)0 (0.0%)1 (1.7%)0 (0.0%)2 (0.5%)4 (1.3%)
650 (0.0%)0 (0.0%)0 (0.0)%0 (0.0%)1 (0.3%)0 (0.0%)
700 (0.0%)0 (0.0%)0 (0.0)%0 (0.0%)12 (3.2%)7 (2.3%)
711 (1.1%)0 (0.0%)1 (1.7%)1 (1.6%)4 (1.1%)11 (3.6%)
752 (2.3%)1 (3.3%)1 (1.7%)3 (4.9%)8 (2.1%)6 (2.0%)
770 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.3%)0 (0.0%)
780 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.3%)1 (0.3%)
810 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)3 (0.8%)4 (1.3%)

(c)

HIV positive femalesHIV positive malesHealthy renal donors
HLA DRTB neg. FTB pos. FTB neg. MTB pos. MFemalesMales

15 (5.7%)3 (10.0%)6 (10.2%)5 (8.2%)17 (4.52%)19 (6.21%)
30 (0.0%)0 (0.0%)1 (1.7%)0 (0.00%)9 (2.39%)9 (2.94%)
420 (22.7%)5 (16.7%)17 (28.8%)13 (21.3%)39 (10.37%)40 (13.07%)
722 (25.0%)5 (16.7%)8 (13.6%)11 (18.0%)72 (19.15%)44 (14.38%)
83 (3.4%)0 (0.0%)1 (1.7%)7 (11.5%)3 (0.80%)8 (2.61%)
90 (0.0%)0 (0.0%)1 (1.7%)1 (1.6%)0 (0.00%)5 (1.63%)
1011 (12.5%)3 (10.0%)9 (15.3%)11 (18.0%)36 (9.57%)24 (7.84%)
119 (10.2%)3 (10.0%)6 (10.2%)9 (14.8%)20 (5.32%)25 (8.17%)
123 (3.4%)1 (3.3%)4 (6.8%)2 (3.3%)14 (3.72%)17 (5.56%)
1313 (14.8%)6 (20.0%)12 (20.3%)10 (16.4%)47 (12.50%)22 (7.19%)
1420 (22.7%)4 (13.3%)11 (18.6%)10 (16.4%)34 (9.04%)23 (7.52%)
1547 (53.4%)17 (56.7%)26 (44.1%)26 (42.6%)105 (27.93%)98 (32.03%)
164 (4.5%)2 (6.7%)1 (1.7%)0 (0.00%)4 (1.06%)5 (1.63%)
173 (3.4%)1 (3.3%)3 (5.1%)7 (11.5%)9 (2.39%)10 (3.27%)
180 (0.0%)1 (3.3%)0 (0.0%)0 (0.00%)0 (0.00%)3 (0.98%)

*Using Chi-square test, the significance of frequency distribution of various HLA alleles was compared between males and females of HIV subjects with and with out TB as well as in healthy renal donors. The only significant observation noted was lower occurrence of TB in HLAB57 positive HIV infected women ( ).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.